Vytrus Biotech Marks Historic 2024 with Sustainability Milestones and 35% Revenue Growth

Vytrus Biotech, a biotechnology company that develops active ingredients for dermocosmetics and healthcare, has published its 2024 Sustainability Report, which adds to the first one already published, thus covering the company’s trajectory until 2023.

With the aim of being a global leader in innovation and sustainability, the company uses its own technology based on plant stem cells. This method allows for savings of up to 99% in natural resources, compared to traditional systems.

Vytrus Biotech has classified 2024 as a historic year due to its financial results

Other highlights included the renewal of the company’s ISO 9001, COSMOS, GMP, and Innovative SME certifications, as well as the Ecovadis Platinum Medal, Muncunill Innovation Award, and Cosméticaforum Award. In terms of product innovation, the active ingredient Baolift ™ (a natural derivative of the baobab tree with a lifting effect) was launched and received international recognition. Additionally, the company introduced the ” Fit Skin ” concept , which promotes fit, toned, and rejuvenated skin.

Furthermore, its ESG and sustainability strategy has been based on Vytrus Biotech’s adherence to the UN Global Compact and the redefinition of its ESG strategy with Roots for Sustainability. It has actively participated in the Sustainable SME Phase II program and has activated three key commitments: generating a positive impact on people and nature, creating shared value for our customers, and maintaining good corporate governance.

In turn, in terms of environmental and social commitment, the Water Project achieved savings of 64,000 tons of water in 2024, contributing to a total savings of 200,000 tons over four years. The carbon footprint for 2024 was 358.66 tons of CO2e (Scopes 1, 2, and 3). In addition, Vytrus Biotech collaborates with Prodis on its Diversity Plan and made a solidarity donation due to the floods in the Valencian Community.

Likewise, Vytrus Biotech’s value chain and marketing have achieved nine new patent validations . They have also launched their direct sales model in Spain and France . Another milestone has been improving the sustainability of their supply chain, using 100% recyclable packaging, reducing waste through bulk purchasing, and employing reusable materials in marketing.

Vytrus Biotech has classified 2024 as a historic year due to its financial results. They achieved a turnover of €5 million, representing a 35% increase, an EBITDA of €2 million, representing a 55% growth , and a net profit of €1 million.

__

(Featured image by Ransford Quaye via Unsplash)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in Ei Estrategias de Inversion. A third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us